Latest
-
A great leap forward in the war against Alzheimer’s disease
Cover Story The approval of the first drug to treat the neurodegenerative disease in 18 years will galvanise research in the entire subsector, says Dr Mike Tubbs. That bodes well for Huntingdon’s and Parkinson’s sufferers too
Cover Story -
Why Joe Biden’s Big Pharma patent grab is a terrible idea
Briefings The US president has proposed waiving patents on Covid-19 vaccines in a bid to boost global supply. But it won’t work on its own terms and holds dangers for the future.
Briefings -
How to invest in the fight against Alzheimer’s disease
Cover Story The cost of caring for those with dementia is a growing problem for healthcare systems around the world. Any firm that develops an effective treatment could stand to make a fortune, reports Matthew Partridge.
Cover Story -
A show of support for GlaxoSmithKline's hedge fund fight
News Several large shareholders have said that they will support GlaxoSmithKline in its battle with hedge fund Elliott Management.
News -
How to invest in biotechnology: the healthcare sector’s high-growth area
Cover Story Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment strategies and highlights his favourite picks.
Cover Story -
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
News -
Vaccine patents: a bitter pill for drug companies
News The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.
News -
Activist investor Elliott takes takes a stake in Glaxo
News Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
News -
The unscientific criticism of AstraZeneca could do lasting damage
News Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
News
